NCT02576431: Study of LOXO-101 (Larotrectinib) in Subjects With NTRK Fusion Positive Solid Tumors (NAVIGATE)

NCT02576431
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: NTRK
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 12 Years and older (Child, Adult, Senior)
Location of Metastases: 
Additional Notes: Must have tumor with NTRK 1/2/3 gene fusion
Exclusions: 
https://ClinicalTrials.gov/show/NCT02576431

Comments are closed.

Up ↑